139.41MMarket Cap-853P/E (TTM)
20.0000High19.5300Low1.35KVolume19.5300Open19.5900Pre Close26.65KTurnover0.04%Turnover RatioLossP/E (Static)7.05MShares24.400052wk High1.21P/B69.63MFloat Cap10.000052wk Low--Dividend TTM3.52MShs Float382.6000Historical High--Div YieldTTM2.40%Amplitude8.0000Historical Low19.7100Avg Price1Lot Size
Cidara Therapeutics Stock Forum
Cidara Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(9.99%),Peter Kolchinsky(9.99%), etc.
Cash available will sustain the operations for 24 months (exclude 105mil private placement). Upcoming catalyst September 2025.
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenzau
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the first sub...
Dow Jones· 1 min ago
No comment yet